U.S. Markets closed

SciClone enters new agreement for Zadaxin import into China

SciClone disclosed in a regulatory filing that on January 18, SciClone Pharmaceuticals, through its subsidiary SciClone Pharmaceuticals International China Holding, entered into a new agreement under which Zadaxin will be imported into the People’s Republic of China. Under the re-exportation agreement with Sinopharm Holding Hong Kong and Sinopharm Holding Lingyun Biopharmaceutical, the re-exporter will purchase Zadaxin from the company’s subsidiary, which the Importer will import into the People’s Republic of China for further distribution. The re-exporter’s and importer’s rights under the agreement are exclusive during the term of the agreement, which expires December 31, 2015.